These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20856833)

  • 1. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.
    Yatuv R; Robinson M; Dayan-Tarshish I; Baru M
    Int J Nanomedicine; 2010 Sep; 5():581-91. PubMed ID: 20856833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.
    Yatuv R; Robinson M; Dayan I; Baru M
    Expert Opin Drug Deliv; 2010 Feb; 7(2):187-201. PubMed ID: 20095942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
    Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
    Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.
    Yatuv R; Dayan I; Carmel-Goren L; Robinson M; Aviv I; Goldenberg-Furmanov M; Baru M
    Haemophilia; 2008 May; 14(3):476-83. PubMed ID: 18393980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
    Spira J; Plyushch OP; Andreeva TA; Andreev Y
    Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.
    Mei B; Pan C; Jiang H; Tjandra H; Strauss J; Chen Y; Liu T; Zhang X; Severs J; Newgren J; Chen J; Gu JM; Subramanyam B; Fournel MA; Pierce GF; Murphy JE
    Blood; 2010 Jul; 116(2):270-9. PubMed ID: 20194895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
    Dayan I; Robinson M; Baru M
    Haemophilia; 2009 Sep; 15(5):1006-13. PubMed ID: 19486171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.
    Peng A; Kosloski MP; Nakamura G; Ding H; Balu-Iyer SV
    AAPS J; 2012 Mar; 14(1):35-42. PubMed ID: 22173945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
    Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
    Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
    Spira J; Plyushch OP; Andreeva TA; Khametova RN
    Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.
    Ramani K; Purohit V; Miclea R; Gaitonde P; Straubinger RM; Balu-Iyer SV
    J Pharm Sci; 2008 Sep; 97(9):3753-64. PubMed ID: 18300296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors.
    Yasumoto A; Madoiwa S; Kashiwakura Y; Ishiwata A; Ohmori T; Mizukami H; Ozawa K; Sakata Y; Mimuro J
    Thromb Res; 2013 May; 131(5):444-9. PubMed ID: 23566532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells.
    Yatuv R; Carmel-Goren L; Dayan I; Robinson M; Baru M
    J Control Release; 2009 Apr; 135(1):44-50. PubMed ID: 19135487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
    Margaritis P
    Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.
    Margaritis P; Arruda VR; Aljamali M; Camire RM; Schlachterman A; High KA
    J Clin Invest; 2004 Apr; 113(7):1025-31. PubMed ID: 15057309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor (F)VIII/VIIa enhances global haemostatic function in the co-presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor.
    Nogami K; Matsumoto T; Yada K; Ogiwara K; Furukawa S; Shida Y; Takeyama M; Shima M
    Br J Haematol; 2018 May; 181(4):528-536. PubMed ID: 29611182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.